In July, anticipating the loss of its near-blockbuster Cubicin in a couple of years, Cubist (CBST) has made two acquisitions: Optimer (NASDAQ:OPTR) and Trius (TSRX) for up to $1.6 billion in total. Along with the companies, Cubist acquired the drugs Dificid and tedizolid, two of the most promising new antibiotics around.
The deals would give Cubist one antibiotic already on the market and another one that has passed all three phases of clinical trials necessary for FDA approval.
Dificid was the first antibacterial drug approved in more than 25 years to treat CDAD (Clostridium difficile-associated diarrhea).
Approved in May 2011, Dificid has FDA-labeled superiority for sustained response versus oral vancomycin, the so-called "last resort"...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|